Search

Background: The etiology of diabetic kidney disease is complex, and the role of lipoproteins and their lipid components in the development of the disease cannot be ignored. However, phospholipids are an essential component, and no Mendelian randomization studies have yet been conducted to examine potential causal associations between phospholipids and diabetic kidney disease. Methods: Relevant exposure and outcome datasets were obtained through the GWAS public database. The exposure datasets included various phospholipids, including those in LDL, IDL, VLDL, and HDL. IVW methods were the primary analytical approach. The accuracy of the results was validated by conducting heterogeneity, MR pleiotropy, and F-statistic tests. MR-PRESSO analysis was utilized to identify and exclude outliers. Results: Phospholipids in intermediate-density lipoprotein (OR: 0.8439; 95% CI: 0.7268–0.9798), phospholipids in large low- density lipoprotein (OR: 0.7913; 95% CI: 0.6703–0.9341), phospholipids in low- density lipoprotein (after removing outliers, OR: 0.788; 95% CI: 0.6698–0.9271), phospholipids in medium low- density lipoprotein (OR: 0.7682; 95% CI: 0.634–0.931), and phospholipids in small low-density lipoprotein (after removing outliers, OR: 0.8044; 95% CI: 0.6952–0.9309) were found to be protective factors. Conclusions: This study found that a higher proportion of phospholipids in intermediate-density lipoprotein and the various subfractions of low-density lipoprotein, including large LDL, medium LDL, and small LDL, is associated with a lower risk of developing diabetic kidney disease. [ABSTRACT FROM AUTHOR]

To investigate the clinical characteristics, vascular imaging features, and prognosis of Takayasu's arteritis (TA) patients with stroke in China. Medical charts of 411 in-patients who fulfilled the classification criteria of modified 1990 American College of Rheumatology (ACR) criteria for TA and with complete data from 1990 to 2014 were reviewed retrospectively. The demographic data, symptoms and signs, laboratory test results, radiological features, treatment, and interventional or surgical procedures were collected and analyzed. Patients with radiological confirmed stroke were identified. Chi-square test or Fisher exact test was used to compare the differences between patients with and without stroke. Twenty-two patients with ischemic stroke (IS) and 4 patients with hemorrhagic stroke were identified. The incidence of stroke in TA patients was 6.3% (26/411), of which 11 patients were considered to be the initial manifestation. Stroke patients had more visual acuity loss (15.4% vs. 4.7%, P = 0.042). Systemic inflammatory symptoms and inflammatory markers were less common in patients with stroke than in those without stroke [fever P = 0.007; erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), P < 0.001]. Cranial angiography showed that common carotid artery (CCA) (73.0%, 19/26) and subclavian artery (SCA) (73.0%, 19/26) were the most involved, followed by internal carotid artery (ICA) (57.7%, 15/26) in stroke patients. The intracranial vascular involvement rate of stroke patients was 38.5% (10/26); the middle cerebral artery (MCA) was the most common artery involved. The most common site of stroke was the basal ganglia region. The occurrence of intracranial vascular involvement was much higher in patients with stroke when compared to patients without stroke (38.5% vs. 5.5%, P < 0.001). Among all patients with intracranial vascular involvement, patients without stroke received more aggressive treatment than patients with stroke (90.4% vs. 20.0%, P < 0.001). There was no significant increase in in-hospital mortality in patients with stroke compared with patients without stroke (3.8% vs. 2.3%, P = 0.629). Stroke is the initial presentation in 50% of TA patients with stroke. The intracranial vascular involvement rate is significantly increased in stroke patients than in patients without stroke. The artery invloved in patients with stroke are cervical artery and intracranial involvement. Systemic inflammation is less in patients with stroke. Aggressive treatment for TA with glucosteroid (GC) and immunosuppressive agents combined with anti-stroke therapy is needed to improve the prognosis of TA complicated stroke. [ABSTRACT FROM AUTHOR]

Nanofertilizers can be used as potential contenders to provide macro- and micronutrients to plants. Specifically, iron-oxide-based engineered nanoparticles are promising candidates for next-generation iron-deficiency fertilizers. Aiming to investigate the effect of Fe2O3 magnetic nanoparticles on plant germination and growth, alfalfa seeds were presoaked by a series of concentrations (0, 50, 100, 150, and 200 mg/L) of Fe2O3 NPs in this study. The germination rate, root length, chlorophyll content, and activity of the antioxidant enzymes (superoxide dismutase (SOD), peroxidase (POD), and catalase (CAT)) were detected. Further, hydroponic alfalfa young seedlings were treated with 50 mg/L Fe2O3 NPs, with 50 mg/L Fe-EDTA as the control. The growth index, chlorophyll content, metal (Fe, Cu, Zn, and Mn) content, and ferric-chelate reductase activity were detected. The results indicated that the presoaking of Fe2O3 NPs promoted alfalfa seed germination in all treatments. Short-time of Fe2O3 NPs presoaking has not affected chlorophyll and iron content while increasing antioxidase (SOD, POD, and CAT) activities at 50 and 200 mg/L concentrations. Fe2O3 NPs of 50 mg/L have the most beneficiary impact on alfalfa seed germination by presoaking. Fe2O3 NPs of 50 mg/L enhanced the seedlings' growth and increased chlorophyll content, Fe content, and Mn content of hydroponic alfalfa compared with the control. Moreover, ferric chelate reductase activity was significantly lower in alfalfa roots exposure to Fe2O3 NPs than in the control. The results showed that 50 mg/L Fe2O3 NPs could be used as an appropriate and effective treatment concentration for seed pretreatment and fertilizer application. The growth-promoting effect of Fe2O3 NPs on alfalfa is related to its nanostructured properties. More in-depth research is still needed to understand the growth-promoting mechanism of Fe2O3 NPs and the impact of Fe2O3 NPs on the field environment. [ABSTRACT FROM AUTHOR]

Leflunomide is a classic disease‐modifying anti‐rheumatic drug that is widely used to treat autoimmune diseases. Studies also show its antiviral effects in in vitro and/or in vivo experiments. Considering glucocorticoids, immunosuppressants and newly emerged antibodies commonly used in autoimmune diseases and autoinflammatory disorders bring risk of infection such as viral infection, leflunomide with combination of anti‐viral and immunosuppressive features to maintain the balance between infection and anti‐inflammation are attractive. Here we summarize the actions and mechanisms of leflunomide in immunoregulatory and antiviral effects. [ABSTRACT FROM AUTHOR]